Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:44:26.552Z.
Calculation as of: 2026-10-06T16:44:26.552Z.
Quote observation: 2026-10-06T16:39:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8d1468b7a76ea597d68349990a611a16a2ef6f087c77b10e193910d6856baa6d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $29.60M | N/A | N/A | N/A | N/A |
| OneMedNet Corporation (ONMD)vs › | $29.70M | N/A | 3.61x | 3.61x | 3.61x |
| Context Therapeutics Inc. (CNTX)vs › | $29.48M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.88M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $31.02M | N/A | N/A | N/A | N/A |
| MDxHealth S.A. (MDXH)vs › | $29.99M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.23M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $30.69M | N/A | N/A | N/A | N/A |
| SCYNEXIS, Inc. (SCYX)vs › | $30.94M | N/A | 2.93x | 2.93x | 2.93x |
| aTyr Pharma, Inc. (ATYR)vs › | $28.49M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute